Test ELISA in vitro per valutare la potenza del vaccino contro la rabbia

Overview

This article describes an indirect ELISA sandwich immunocapture method for determining the immunogenic glycoprotein contents in rabies vaccines. The test utilizes a neutralizing Monoclonal Antibody (mAb-D1) that recognizes glycoprotein trimers, providing an alternative to the in vivo NIH test for assessing vaccine potency.

Key Study Components

Area of Science

• Immunology
• Vaccinology
• In vitro testing methods

Background

• The WHO encourages the development of in vitro approaches to reduce animal testing.
• Variability in the NIH test has prompted the search for more consistent alternatives.
• This ELISA test demonstrates good concordance with classical NH tests.
• High sensitivity and rapid execution within one day are key advantages of this method.

Purpose of Study

• To evaluate rabies vaccine potency using an in vitro ELISA method.
• To provide a reliable alternative to the in vivo NIH test.
• To promote the use of this method among manufacturers and national control laboratories.

Methods Used

• Indirect ELISA sandwich immunocapture technique.
• Use of neutralizing Monoclonal Antibody (mAb-D1).
• Preparation of pre-sized volumes in duplicate for each dilution.
• Decontamination procedures for handling contaminated materials.

Main Results

• The ELISA test shows high sensitivity in recognizing the immunogenic form of the glycoprotein.
• Results are consistent with those obtained from classical NH tests.
• The method can be completed in a single day, enhancing efficiency.
• Promoted as a viable alternative by manufacturers and control laboratories.

Conclusions

• The ELISA method is a promising alternative for evaluating rabies vaccine potency.
• It aligns with WHO recommendations to reduce animal testing.
• Further adoption could standardize vaccine potency assessments.

Frequently Asked Questions